Simulations Plus, Inc. (SLP)
Stock Price Chart
Key Info
| Market Cap | 1.23B |
| Revenue (ttm) | 40.07M |
| Net Income (ttm) | 9.20M |
| Shares Out | 17.82M |
| EPS (ttm) | 0.51 |
| PE Ratio | 123.22 |
| Forward PE | 96.15 |
| Dividend | $0.24 |
| Dividend Yield | 0.38% |
Stock Quote
| Trading Day | Aug 11, 2020 |
| Last Price | $62.84 |
| Previous Close | $64.91 |
| Change ($) | -2.07 |
| Change (%) | -3.19% |
| Day's Open | 64.40 |
| Day's Range | 62.58 - 65.79 |
| Day's Volume | 186,841 |
| 52-Week Range | 26.00 - 73.58 |
More Stats
| Market Cap | 1.23B |
| Enterprise Value | 1.23B |
| Earnings Date (est) | Nov 11, 2020 |
| Ex-Dividend Date | Jul 24, 2020 |
| Shares Outstanding | 17.82M |
| Float | 13.40M |
| EPS (basic) | 0.53 |
| EPS (diluted) | 0.51 |
| FCF / Share | 0.45 |
| Dividend | $0.24 |
| Dividend Yield | 0.38% |
| Earnings Yield | 0.81% |
| FCF Yield | 0.64% |
| Payout Ratio | n/a |
| Shares Short | 1.78M |
| Short Ratio | 5.66 |
| Short % of Float | 11.82% |
| Beta | -0.08 |
| PE Ratio | 123.22 |
| Forward PE | 96.15 |
| P/FCF Ratio | 155.78 |
| PS Ratio | 30.79 |
| PB Ratio | 24.90 |
| Revenue | 40.07M |
| Operating Income | 11.35M |
| Net Income | 9.20M |
| Free Cash Flow | 7.92M |
| Net Cash | 6.34M |
| Net Cash / Share | 0.32 |
| Gross Margin | 62.25% |
| Operating Margin | 28.32% |
| Profit Margin | 23.00% |
| FCF Margin | 19.77% |
| ROA | 14.91% |
| ROE | 22.30% |
| ROIC | n/a |
Analyst Summary
Analyst Consensus: Buy
Financial Performance
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 33.97 | 29.67 | 24.14 | 19.97 | 18.31 | 11.46 | 10.07 | 9.45 | 8.74 | 10.71 |
| Revenue Growth | 14.51% | 22.9% | 20.86% | 9.05% | 59.8% | 13.8% | 6.58% | 8.12% | -18.42% | - |
| Gross Profit | 24.94 | 21.67 | 17.83 | 15.37 | 13.92 | 9.83 | 8.42 | 7.94 | 7.18 | 8.17 |
| Operating Income | 10.65 | 10.30 | 8.26 | 7.23 | 5.86 | 4.44 | 4.07 | 3.61 | 3.53 | 2.87 |
| Net Income | 8.58 | 8.93 | 5.79 | 4.95 | 3.84 | 3.03 | 2.89 | 3.03 | 2.71 | 2.16 |
| Shares Outstanding | 17.49 | 17.33 | 17.24 | 17.03 | 16.86 | 16.17 | 16.00 | 15.76 | 15.54 | 15.83 |
| Earnings Per Share | 0.48 | 0.50 | 0.33 | 0.29 | 0.23 | 0.18 | 0.18 | 0.19 | 0.17 | 0.13 |
| EPS Growth | -4% | 51.52% | 13.79% | 26.09% | 27.78% | 0% | -5.26% | 11.76% | 30.77% | - |
| Dividend Per Share | 0.24 | 0.24 | 0.20 | 0.20 | 0.20 | 0.19 | 0.25 | 0.15 | - | - |
| Dividend Growth | 0% | 20% | 0% | 0% | 5.26% | -24% | 66.67% | - | - | - |
| Operating Cash Flow | 11.64 | 9.29 | 6.88 | 5.42 | 7.14 | 5.31 | 2.56 | 3.78 | 3.50 | 2.91 |
| Capital Expenditures | -1.96 | -2.33 | -1.56 | -1.23 | -1.24 | -3.89 | -1.18 | -1.07 | -0.82 | -0.94 |
| Free Cash Flow | 9.68 | 6.96 | 5.32 | 4.18 | 5.90 | 1.41 | 1.38 | 2.72 | 2.68 | 1.97 |
| Cash & Equivalents | 11.44 | 9.40 | 6.22 | 8.03 | 8.55 | 8.61 | 10.18 | 12.70 | 10.18 | 9.63 |
| Net Cash / Debt | 11.44 | 9.40 | 6.22 | 8.03 | 8.55 | 8.61 | 10.18 | 12.70 | 10.18 | 9.63 |
| Assets | 45.20 | 43.28 | 38.51 | 27.81 | 27.34 | 20.98 | 16.06 | 17.35 | 15.87 | 14.66 |
| Liabilities | 7.52 | 11.36 | 12.71 | 5.08 | 7.81 | 5.55 | 1.82 | 2.20 | 1.83 | 1.61 |
| Book Value | 37.68 | 31.92 | 25.80 | 22.73 | 19.53 | 15.44 | 14.24 | 15.14 | 14.04 | 13.05 |
Company Profile
Company Details
| Full Name | Simulations Plus, Inc. |
| Country | United States |
| Employees | 107 |
| CEO | Shawn M. O'Connor |
Stock Information
| Ticker Symbol | SLP |
| Stock Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Health Information Services |
| Unique Identifier | NASDAQ: SLP |
| IPO Date | June 18, 1997 |
Description
Simulations Plus, Inc. develops drug discovery and development software for mechanistic modeling and simulation, and machine-learning-based prediction of properties of molecules from their structure worldwide. The company offers GastroPlus, which simulates the absorption, pharmacokinetics (PK), pharmacodynamics, and drug-drug interactions of compounds administered to humans and animals; DDDPlus that simulates in vitro laboratory experiments that measure the rate of dissolution of the drug and additives in a dosage form; and MembranePlus, which simulates laboratory experiments. It also provides PKPlus, a standalone program that provides the functionality needed by pharmaceutical industry scientists to perform the analyses and generate the outputs needed to satisfy regulatory agency requirements for NCA and compartmental PK modelling; ADMET Predictor, a chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, a molecule drawing program or sketcher. In addition, it offers MedChem Studio, a software tool for data mining and designing new molecules; KIWI, a cloud-based Web application to organize, process, maintain, and communicate the volume of data and results generated by pharmacologists and scientists over the duration of a drug development program; DILIsym, a quantitative systems pharmacology software; NAFLDsym, a simulation program for analyzing nonalcoholic fatty liver disease; and RENAsym for investigating and predicting drug-induced or acute kidney injury. Further, the company provides population modeling and simulation contract research services for the pharmaceutical and biotechnology industries; and clinical-pharmacology-based consulting services in support of regulatory submissions. It sells its pharmaceutical/chemistry software to pharmaceutical, biotechnology, agrochemical, cosmetics, and food companies. The company was founded in 1996 and is headquartered in Lancaster, California.